scholarly journals High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia

Viruses ◽  
2018 ◽  
Vol 10 (2) ◽  
pp. 60 ◽  
Author(s):  
Birkneh Tadesse ◽  
Natalie Kinloch ◽  
Bemuluyigza Baraki ◽  
Hope Lapointe ◽  
Kyle Cobarrubias ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Southern Ethiopia ◽  
First Line ◽  
Dual Class

scholarly journals Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy

AIDS ◽  
2013 ◽  
Vol 27 (4) ◽  
pp. 553-561 ◽  
Author(s):  
Mary-Ann A. Etiebet ◽  
James Shepherd ◽  
Rebecca G. Nowak ◽  
Man Charurat ◽  
Harry Chang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
First Line ◽  
Hiv 1

scholarly journals Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia

2019 ◽  
Vol 24 (4) ◽  
pp. 291-300
Author(s):  
F Parker Hudson ◽  
Lloyd Mulenga ◽  
Andrew O Westfall ◽  
Ranjit Warrier ◽  
Aggrey Mweemba ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Virological Failure ◽  
First Line ◽  
Hiv 1

scholarly journals Moderate Levels of Pretreatment HIV Drug Resistance — Zimbabwe, April–July 2015

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S424-S424
Author(s):  
Juliana Da Silva ◽  
Janet Dzangare ◽  
Elizabeth Gonese ◽  
Mutsa Mhangara ◽  
Owen Mugurungi ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Reverse Transcriptase ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Transcriptase Inhibitor ◽  
World Health ◽  
First Line ◽  
Cross Sectional ◽  
Hiv Drug Resistance ◽  
Reverse Transcriptase Inhibitor

Abstract Background The World Health Organization (WHO) HIV Drug Resistance (HIVDR) report 2012 demonstrated that the levels of HIVDR to first-line antiretroviral therapy (ART) are increasing. This finding threatens to reverse a decade of gains in HIV/AIDS epidemic control. The WHO Global Action Plan for HIVDR emphasizes strengthening surveillance of drug resistance through the implementation of national cross-sectional surveys. We conducted such survey to determine the prevalence of HIVDR among ART-naive patients in Zimbabwe and to describe the profile of the surveillance drug resistance mutations (SDRM) encountered in the country. Methods A prospective, nationally representative, cross-sectional survey was conducted in 35 clinical sites selected using two stage probability proportional to size sampling. Patients were enrolled during April–July 2015. Specimens were sent for genotyping to CDC Atlanta. SDRM were interpreted using Stanford HIV Drug Resistance Database classification. Results A total of 361 subjects were surveyed. Most participants were female (60.3%) and the median age was 35.8 years. Thirty-four out of 361subjects presented with ≥1 SDRM (9.4%, 95% confidence interval: 6.8–12.8%) prior to initiation antiretroviral therapy (ART). Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations were the most commonly detected mutation (n = 30). Only two patients presented with a nucleoside reverse transcriptase inhibitor mutation and one patient presented with a protease inhibitor mutation. In two patients, ≥3 SDRMs were detected, which may suggest they were not truly ART-naïve. Conclusion This study provides national estimates of HIVDR in a high burden country with broad access to ART and provides valuable inisight on the state of HIVDR in such setting. Zimbabwe has reached moderate levels of HIVDR in ART-naive patients, as specified by the WHO classification. These levels may impact the ability to achieve viral suppression in a significant number of patients initiating standard ART regimens in Zimbabwe, where NNRTI-based regimens are used as the first line. The use of drugs with high resistance barrier, such as dolutegravir, may improve the care of patients in the developing world, where individualized pretreatment genotype is not feasible. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document